SOLIGENIX, INC. Deferred Tax Assets, Operating Loss Carryforwards, Domestic
SOLIGENIX, INC. (SNGX) had Deferred Tax Assets, Operating Loss Carryforwards, Domestic of $24.00 million as of 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Income Taxes › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Operating Loss Carryforwards, Components
us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic · last filed 2026-03-31
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Domestic $24.00M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Domestic $21.90M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Domestic $12.90M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Domestic $13.20M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards, Domestic | Deferred Tax Assets, Operating Loss Carryforwards, Domestic as first filed |
|---|---|---|
| 2025-12-31 | $24.00M 10-K · filed 2026-03-31 | |
| 2024-12-31 | $21.90M 10-K · filed 2025-03-21 | |
| 2023-12-31 | $12.90M 10-K · filed 2024-03-15 | |
| 2022-12-31 | $13.20M 10-Q · filed 2023-11-13 | |
| 2021-12-31 | $25.20M 10-Q · filed 2022-05-13 | |
| 2020-12-31 | $20.00M 10-Q · filed 2021-11-12 | $25.00M 10-K · filed 2021-03-30 |
| 2019-12-31 | $16.18M 10-Q · filed 2020-11-12 | |
| 2018-12-31 | $14.03M 10-Q · filed 2019-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |